Director, In vitro Biology / JLSa2 Therapeutics

Dr. Linya Wang is a dedicated biotechnology and pharmaceutical research leader with a robust background in advancing complex therapeutic development. With extensive expertise in assay development, cell biology, immunology, and drug discovery, she has established herself as a subject matter expert capable of driving high-impact research programs from initial concept through execution.

Dr. Wang’s versatile career spans high-growth mid-sized biotech environments and dynamic startup settings. At mid-sized innovators like Twist Bioscience, she leveraged rigorous operational frameworks to streamline assay pipelines and advance antibody discovery programs. Complementing this experience, her work in nimble startup environments like JLSa2 demonstrated her ability to thrive in fast-paced, resource-conscious settings by establishing foundational lab infrastructure, designing key functional assays, and solving complex biological questions under aggressive timelines.

Across these diverse organizational scales, Dr. Wang has consistently bridged foundational cell biology with strategic pipeline goals. She possesses a proven track record in the characterization of biologics, troubleshooting intricate technical challenges, and leading cross-functional collaborations that de-risk target validation and accelerate early-stage drug discovery.

Beyond her corporate leadership, Dr. Wang is actively committed to driving broader industry connection and scientific community impact. Through her contributions to organizations such as the Bay Area Taiwanese Biotechnology Association (BATBA) and Taiwan Tech Summit, she organizes spotlight initiatives, fosters cross-institutional collaboration, and empowers emerging talent. Dedicating her career to both scientific excellence and ecosystem building, Dr. Wang continues to advocate for collaborative innovation to advance next-generation therapies.

王琳雅博士（Dr. Linya Wang）是一位致力於推動複雜藥物開發的生物科技與製藥研究領導者。憑藉在分析方法開發（assay development）、細胞生物學、免疫學及藥物發現領域的深厚專業知識，她已確立了作為領域專家（SME）的地位，具備引導高影響力研究計畫從初始概念走向具體執行的卓著能力。

王博士豐富的職涯跨足高成長的中型生技企業與充滿動力的初創公司。在如 Twist Bioscience 等中型創新企業任職期間，她善用嚴謹的營運架構來簡化分析流程，並推進抗體發現計畫。與此相輔相成的是，她在如 JLSa2 等敏捷初創環境中的工作經歷，展現了她在節奏快速且資源受限的環境中茁壯成長的能力——不僅建立基礎實驗室設施、設計關鍵功能性分析，更在緊迫的時間表下解決複雜的生物學問題。

跨越不同規模的組織，王博士始終如一地將基礎細胞生物學與策略性藥物管線目標緊密結合。她在生物製劑特性分析、排解複雜技術難題，以及領導跨領域合作以降低目標驗證風險並加速早期藥物發現方面，擁有卓著的實績。

除了企業內的領導職責，王博士亦積極致力於推動更廣泛的產業連結與科學社群影響力。透過參與舊金山灣區台灣生物科技協會（BATBA）及台灣科技峰會（Taiwan Tech Summit）等組織，她協助籌劃焦點活動、促進跨機構合作並賦能新興人才。王博士將事業奉獻於追求卓越科學與建構產業生態系，持續倡導合作創新，以推進下一代療法的發展。